Status:
RECRUITING
Non Invasive Imaging Methods for Detecting PA：a Clinical PET Study of 18F-Pentixather
Lead Sponsor:
Fangfang Sun
Conditions:
Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Primary aldosteronism (PA) is the most common endocrine cause of hypertension. 68Ga-pentixafor PET/CT possesses a relatively high sensitivity and specificity for Aldosterone producing adenoma (APA) de...
Eligibility Criteria
Inclusion
- Patients diagnosed with primary aldosteronism and willing to undergo surgery
- Clinically highly suspected of primary aldosteronism, but the diagnostic test cannot clearly identify the patients
- Postoperative recurrence in patients with primary aldosteronism
Exclusion
- Pregnant and lactating women.
- Patients with poor autonomous behavior ability, severe claustrophobia, and critically ill patients requiring life support who are unable to cooperate in completing the examination.
- There are other situations where patients are not suitable for this examination
Key Trial Info
Start Date :
June 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06581744
Start Date
June 12 2024
End Date
June 30 2026
Last Update
September 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China, 116022